LPLuciana Pizzatti

Luciana Pizzatti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luciana Pizzatti has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glyphosate as a Food Contaminant: Main Sources, Detection Levels, and Implications for Human and Public Health

    by Juliana Maria Bitencourt de Morais Valentim, Carolina Coradi, Natália Prudêncio Viana, Tatiane Renata Fagundes, Pâmela Lonardoni Micheletti, Shaiane Carla Gaboardi, Bruna Fadel, Luciana Pizzatti, Luciano Zanetti Pessoa Candiotto, Carolina Panis

    Glyphosate is a broad-spectrum pesticide that has become the most widely used herbicide globally. However, concerns have risen regarding its potential health impacts due to food contamination. Studies have detected glyphosate in human blood and urine samples, indicating human exposure and its persistence in the organism. A growing body of literature has reported the health risks concerning glyphosate exposure, suggesting that the daily intake of contaminated food and water poses a public health concern. Furthermore, countries with high glyphosate usage and lenient regulations regarding food and water contamination may face more severe consequences. In this context, in this review, we examined the literature regarding food contamination by glyphosate, discussed its detection methods, and highlighted its risks to human health.


  • Open Access

    Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database

    by Natália Almeida, Jimmy Rodriguez, Indira Pla Parada, Yasset Perez-Riverol, Nicole Woldmar, Yonghyo Kim, Henriett Oskolas, Lazaro Betancourt, Jeovanis Gil Valdés, K. Barbara Sahlin, et al.

    Plasma analysis by mass spectrometry-based proteomics remains a challenge due to its large dynamic range of 10 orders in magnitude. We created a methodology for protein identification known as Wise MS Transfer (WiMT). Melanoma plasma samples from biobank archives were directly analyzed using simple sample preparation. WiMT is based on MS1 features between several MS runs together with custom protein databases for ID generation. This entails a multi-level dynamic protein database with different immunodepletion strategies by applying single-shot proteomics. The highest number of melanoma plasma proteins from undepleted and unfractionated plasma was reported, mapping >1200 proteins from >10,000 protein sequences with confirmed significance scoring. Of these, more than 660 proteins were annotated by WiMT from the resulting ~5800 protein sequences. We could verify 4000 proteins by MS1t analysis from HeLA extracts. The WiMT platform provided an output in which 12 previously well-known candidate markers were identified. We also identified low-abundant proteins with functions related to (i) cell signaling, (ii) immune system regulators, and (iii) proteins regulating folding, sorting, and degradation, as well as (iv) vesicular transport proteins. WiMT holds the potential for use in large-scale screening studies with simple sample preparation, and can lead to the discovery of novel proteins with key melanoma disease functions.


  • Gene Doping and Genomic Science in Sports: Where Are We?

    by Sheila López, João Meirelles, Vanessa Rayol, Gabriella Poralla, Nicole Woldmar, Bruna Fadel, Mariana Figueiredo, Mônica da Costa Padilha, Francisco Radler de Aquino Neto, Henrique Marcelo Gualberto Pereira, et al.

    The misuse of sport-related gene transfer methods in elite athletes is a real and growing concern. The success of gene therapy in the treatment of hereditary diseases has been most evident since ta...


  • Open Access

    Label-Free Proteomics Revealed Oxidative Stress and Inflammation as Factors That Enhance Chemoresistance in Luminal Breast Cancer

    by Bruno R. B. Pires, Carolina Panis, Vinícius Dias Alves, Ana C. S. A. Herrera, Renata Binato, Luciana Pizzatti, Rubens Cecchini, Eliana Abdelhay

    Breast cancer is the leading cause of cancer-associated death among women worldwide. Its high mortality rate is related to resistance towards chemotherapies, which is one of the major challenges of breast cancer research. In this study, we used label-free mass spectrometry- (MS-) based proteomics to investigate the differences between circulating proteins in the plasma of patients with chemoresponsive and chemoresistant luminal A breast cancer. MS analysis revealed 205 differentially expressed proteins. Furthermore, we used in silico tools to build protein-protein interaction networks. Most of the upregulated proteins in the chemoresistant group were closely related and tightly linked. The predominant networks were related to oxidative stress, the inflammatory response, and the complement cascade. Through this analysis, we identified inflammation and oxidative stress as central processes of breast cancer chemoresistance. Furthermore, we confirmed our hypothesis by evaluating oxidative stress and performing cytokine profiling in our cohort. The connections among oxidative stress, inflammation, and the complement system described in our study seem to indicate a pivotal axis in breast cancer chemoresistance. Hence, these findings will have significant clinical implications for improving therapies to bypass breast cancer chemoresistance in the future.


  • Open Access

    Doping control analysis at the Rio 2016 Olympic and Paralympic Games

    by Henrique Marcelo Gualberto Pereira, Vinicius Figueiredo Sardela, Monica Costa Padilha, Luciana Mirotti, Alessandro Casilli, Fabio Azamor de Oliveira, Gustavo de Albuquerque Cavalcanti, Lucas Martins Lisandro Rodrigues, Amanda Lessa Dutra de Araujo, Rachel Santos Levy, et al.

    This paper summarises the results obtained from the doping control analyses performed during the Summer XXXI Olympic Games (August 3–21, 2016) and the XV Paralympic Games (September 7–18, 2016). The analyses of all doping control samples were performed at the Brazilian Doping Control Laboratory (LBCD), a World Anti‐Doping Agency (WADA)‐accredited laboratory located in Rio de Janeiro, Brazil. A new facility at Rio de Janeiro Federal University (UFRJ) was built and fully operated by over 700 professionals, including Brazilian and international scientists, administrative staff, and volunteers. For the Olympic Games, 4913 samples were analysed. In 29 specimens, the presence of a prohibited substance was confirmed, resulting in adverse analytical findings (AAFs). For the Paralympic Games, 1687 samples were analysed, 12 of which were reported as AAFs. For both events, 82.8% of the samples were urine, and 17.2% were blood samples. In total, more than 31 000 analytical procedures were conducted. New WADA technical documents were fully implemented; consequently, state‐of‐the‐art analytical toxicology instrumentation and strategies were applied during the Games, including different types of mass spectrometry (MS) analysers, peptide, and protein detection strategies, endogenous steroid profile measurements, and blood analysis. This enormous investment yielded one of the largest Olympic legacies in Brazil and South America. Copyright © 2017 John Wiley & Sons, Ltd.


  • Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer

    by C. Panis, R. Binato, S. Correa, V. J. Victorino, V. Dias-Alves, A. C. S. A. Herrera, R. Cecchini, A. N. C. Simão, D. S. Barbosa, L. Pizzatti, et al.

    Although paclitaxel-based chemotherapy is widely used for treating breast cancer, paclitaxel therapy has been associated with several adverse effects. Such adverse effects have primarily been associated with long-term regimens, but some acute effects are being increasingly reported in the literature. In this context, the present study analyzed the systemic proteomic profiles of women diagnosed with breast cancer at the first cycle of short paclitaxel infusion (n = 30). Proteomic profiles thus obtained were compared with those of breast cancer patients without chemotherapy (n = 50), as well as with those of healthy controls (n = 40).


  • Identifying potential markers in Breast Cancer subtypes using plasma label-free proteomics

    by Stephany Corrêa, Carolina Panis, Renata Binato, Ana Cristina Herrera, Luciana Pizzatti, Eliana Abdelhay


  • Clinical proteomics in cancer: Where we are

    by Carolina Panis, Luciana Pizzatti, Gustavo F. Souza, Eliana Abdelhay


  • Running Ahead of Doping: Analytical Advances and Challenges Faced by Modern Laboratories Ahead of Rio 2016

    by Francisco Radler de Aquino Neto, Vinicius Figueiredo Sarderla, Luciana Mirotti, Luciana Pizzatti


  • Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer

    by Carolina Panis, Luciana Pizzatti, Aedra Carla Bufalo, Ana Cristina Herrera, Vanessa Jacob Victorino, Rubens Cecchini, Eliana Abdelhay

    Chemotherapy remains the first-choice option for adjuvant therapy in breast cancer. Here, we investigated the impact of the first chemotherapic cycle of doxorubicin on the plasmatic–proteomic profiling of women diagnosed with breast cancer (n = 87). Blood samples were obtained from the same patient before and after doxorubicin infusion (1 h, 60 mg/m2) and processed for label-free LC-MS proteomic screening. A total of 80 proteins were downregulated after chemotherapy. In silico analysis revealed that the main biological process enrolled was inflammation and canonical pathways involving acute phase proteins. TNF-α, IL-1β, IL-12, TGF-β1, clusterin, and gelsolin were chosen as relevant for further validation. All selected targets presented reduced plasmatic levels after treatment. Our results indicate that doxorubicin downregulated acute phase proteins immediately after its infusion. Since such proteins are cancer promoting, its downregulation could support the effectiveness of doxorubicin along treatment.